)

Centessa Pharmaceuticals (CNTA) investor relations material
Centessa Pharmaceuticals Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key program updates and scientific insights
Significant progress in the orexin agonist program, with ORX-750 and ORX-142 advancing in clinical development.
Orexin agonists are positioned as transformative for narcolepsy and other hypersomnias, targeting the underlying cause rather than symptoms.
ORX-750 features a flexible, once-daily dosing profile, with proprietary design based on crystal structure insights.
Phase 2a CRYSTAL-1 study uses adaptive, real-time dose optimization across NT1, NT2, and IH, aiming for best-in-class efficacy and tolerability.
Data from ORX-142, a more potent molecule, is expected this year, with potential for broader neurodegenerative and neuropsychiatric indications.
Clinical data and competitive landscape
Phase 1 data for ORX-750 showed strong maintenance of wakefulness and favorable safety, with minimal difference from placebo.
Higher doses are needed for NT2 and IH due to intact orexin systems, while NT1 requires lower doses.
Competitor data at World Sleep Congress reinforced confidence in the program and highlighted commercial focus.
Aim to launch one molecule across all three indications, simplifying treatment for physicians and patients.
Enthusiasm among physicians is high, with expectations that orexin agonists could redefine standards of care.
Market opportunity and financial position
Rare hypersomnias represent a market opportunity exceeding $15 billion, with NT1 alone estimated at $6–7 billion.
Cash position of $400 million as of June 30, providing runway into mid-2027.
Intellectual property strategy and medicinal chemistry expertise provide a competitive moat in the orexin agonist space.
AI is leveraged in clinical operations, but human relationships remain central to execution.
Regulatory and tariff risks are considered manageable, with contingencies in place.
Next Centessa Pharmaceuticals earnings date

Next Centessa Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage